Vertex, CRISPR Win World’s First Approval for CRISPR-Edited Therapy from UK

The U.K.’s Medicines and Healthcare products Regulatory Agency on Thursday granted Vertex Pharmaceuticals and CRISPR Therapeutics conditional marketing authorization for their CRISPR/Cas9 gene-edited therapy exagamglogene autotemcel, now to carry the brand name Casgevy, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia.